Company news

Arovella Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Amended Constitution

November 4, 2026

Results of Meeting

November 3, 2026

Results of Meeting

November 3, 2026

Correction to previous CEO appointment announcement

November 3, 2026

Correction to previous CEO appointment announcement

November 3, 2026

2026 AGM Presentation

November 3, 2026

2026 AGM Presentation

November 3, 2026

Arovella Appoints CEO

November 3, 2026

Arovella Appoints CEO

November 3, 2026

Complete tumour clearance in gastric cancer animal study

October 28, 2026

First Patient Dosed with ALA-101

October 26, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 22, 2026

Arovella receives R&D tax rebate of $4.03 million

October 21, 2026

Arovella receives R&D tax rebate of $4.03 million

October 21, 2026

Second Clinical Batch Released for Immediate Patient Use

October 6, 2026

Cell and Gene Innovation Spotlight Presentation

October 6, 2026

Notice of Annual General Meeting/Proxy Form

October 4, 2026

The path to first patient dosing

October 1, 2026

2026 ESG Report

September 16, 2026

Notification of 2026 AGM Date

September 8, 2026

Clinical manufacturing batch released, first site activated

September 6, 2026

Corporate Governance Statement

August 19, 2026

Appendix 4G

August 19, 2026

Appendix 4E and Annual Report

August 19, 2026

Notification regarding unquoted securities - ALA

August 16, 2026

Investor Webinar Presentation

August 11, 2026

Investor Webinar Registration

August 11, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

July 26, 2026

Arovella Appoints Acting CEO

May 6, 2026

Board Refresh and CEO Resignation

May 4, 2026

CLDN18.2 CAR iNKT Cell Preclinical Data Update

March 31, 2026

Half Year Report and Appendix 4D

February 19, 2026

ALA's ind for ALA-101 accepted by the U.S.FDA

January 28, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 22, 2026

Arovella Therapeutics appoints former CSL CSO Dr Andrew Nash as Non-executive Director

November 11, 2025

Positive FDA Type D Meeting Outcome

October 27, 2025

CLDN18.2 CAR-T cells eliminate pancreatic cancer cells

October 2, 2025

Arovella receives R&D tax rebate of $3.21 million

September 22, 2025

S&P DJI Announces September 2025 Quarterly Rebalance

September 5, 2025

Appendix 4E and Annual Report

August 21, 2025

S&P DJI Announces March 2025 Quarterly Rebalance

March 7, 2025

Research Agreement with University of North Carolina

March 3, 2025

Reinstatement to Official Quotation

February 25, 2025

Prospectus

February 25, 2025

Arovella $15m Placement to fund Phase 1

February 25, 2025

Voluntary Suspension

February 9, 2025

Trading Halt

February 5, 2025

Arovella $20m Placement - fully funded to complete Phase 1

January 9, 2025

Arovella receives R&D tax rebate of $3.0 million

October 25, 2024

Positive pre-IND feedback from FDA for ALA-101

August 6, 2024

Older news releases →

Decks

The 5 newest of 45 decks. Every deck is listed under its year.